Natco Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Natco Pharma has appointed Amit Parekh as Executive Vice President - Finance and Accounts of the Company with effect from 2nd December 2025 and as part of the Company's structured succession planning; subject to necessary approvals; Amit Parekh will succeed S.V.V.N. Appa Rao, Chief Financial Officer of the Company at the Board meeting to be held in the month of February 2026.

Powered by Capital Market - Live News

Natco Pharma announced that ICRA has reaffirmed/ assigned the rating ICRA AA; Stable/ ICRA A1+ for various debt facilities of the company.

Powered by Capital Market - Live News

According to the company?s exchange filing, the inspection was carried out between 17 November and 21 November 2025. Natco stated that the observations are procedural in nature and expressed confidence in addressing them comprehensively.

The company added that it remains committed to maintaining cGMP compliance and ensuring the supply of high-quality products to customers and patients worldwide.

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

The company?s consolidated net profit fell 23.5% to Rs 518.40 crore in Q2 FY26, compared with Rs 677.30 crore in Q2 FY25. Revenue from operations declined marginally to Rs 1,363 crore in Q2 FY26, compared with Rs 1,371.10 crore in Q2 FY25.

Powered by Capital Market - Live News

Natco Pharma today announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025.

On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively.

Powered by Capital Market - Live News